At its meeting this week, the PBAC will consider the 'discount rate' but as the national expert advisory body on medicines is not lawfully allowed to provide advice on treatments in the National Medical Stockpile or many of the new therapeutic interventions emerging from company pipelines. What is the real problem? …
This legal quirk of history is a much bigger problem than the 'discount rate'
July 8, 2022 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
This exchange on the HTA Review was about as underwhelming as it sounds
October 9, 2025 - - Latest News -
AusBiotech unveils international conference program for Australia’s biggest week in biotech
October 9, 2025 - - Australian Biotech -
Life sciences industry calls for stronger national strategy to support trials and innovation
October 9, 2025 - - Latest News -
Officials outline ongoing measures to address ADHD medicine shortages
October 9, 2025 - - Latest News -
Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs
October 9, 2025 - - Latest News -
Australian company reports positive outcome from collaboration
October 8, 2025 - - Australian Biotech -
CUREator opens $33 million funding round with CSL and AbbVie partnership
October 8, 2025 - - Latest News